Profile | GDS2987 / GI_25777714-I |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 9.6 | 33 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | 8.5 | 28 |
GSM215254 | HMVEC_atorvastatin_rep1 | 5.8 | 16 |
GSM215282 | HMVEC_atorvastatin_rep3 | 8.6 | 20 |
GSM215344 | HMVEC_atorvastatin_rep2 | 5.8 | 15 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 8.6 | 17 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 26.5 | 47 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 12.3 | 21 |
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | 31.9 | 53 |
GSM215296 | HMVEC_SLx2119_rep3 | 41.7 | 56 |
GSM215297 | PASMC_vehicle_rep1 | 32.7 | 45 |
GSM215298 | PASMC_vehicle_rep2 | 47.2 | 58 |
GSM215310 | PASMC_vehicle_rep3 | 24.1 | 37 |
GSM215311 | PASMC_atorvastatin_rep1 | 55.5 | 65 |
GSM215312 | PASMC_atorvastatin_rep2 | 34.8 | 48 |
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 14.8 | 25 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 29.6 | 49 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 31.1 | 47 |
GSM215327 | PASMC_SLx2119_rep1 | 12.9 | 23 |
GSM215328 | PASMC_SLx2119_rep2 | 1.1 | 2 |
GSM215329 | PASMC_SLx2119_rep3 | 29.1 | 48 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 14.5 | 38 |
GSM215332 | Fibroblasts_vehicle_rep3 | 14 | 42 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 3.9 | 11 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | 4.1 | 11 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 15.5 | 45 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 14.4 | 42 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 8.1 | 23 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 12.8 | 36 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 2.6 | 7 |